- Advertisement -

Related

Accendo: “2016 was a Good Year for us”

- Advertisement -

Stockholm (HedgeNordic) – Activist hedge fund Accendo had another stellar year in 2016 posting net gains of over 30 percent, which adds to an even better 2015 when the fund added 49 percent. In a comment to HedgeNordic, lead portfolio manager Henri Österlund (pictured) explains the underlying drivers for performance in 2016.

HedgeNordic: What transactions were the most profitable during the year?

In 2016 we were able to capitalize work we did over many years with Okmetic, a leading specialty silicon wafer manufacturer based in Finland. Okmetic was sold to a Chinese industrially oriented financial buyer in June and we generated with the investment an annual IRR of 24% over a period of 8+ years.

Other successful transactions included the sale of our position in the Finnish media company Alma Media. The position in Alma Media was a result of an industry consolidation initiative where we as the second largest owner of Talentum actively worked towards and completed the merger between Talentum and Alma Media in 2015.

HedgeNordic: What new investments did you enter into?

New investments included Hexatronic where we built our position as the largest shareholder over multiple block transactions during the year. We also strengthened our position in Doro in 2016 where we are today the largest shareholder. Share performance in Doro was unsatisfactory during 2016, but with the changes on the board of directors and to the top management we look confident on the future.
HedgeNordic: How do you explain the success of the fund recently?
I consider the major source of returns to be a result of the improvements achieved at our portfolio companies and to a lesser extent overall market performance. Our strategy is not based on stock picking, but to invest in a very limited number of companies and then support those realise their full potential.
HedgeNordic: What is your outlook for 2017?
We don’t have a market view for 2017, but focus solely on individual companies where we are invested or consider making an investment into.

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

Jonathan Furelid
Jonathan Furelid
Jonathan Furelid is editor and hedge fund analyst at HedgeNordic. Having a background allocating institutional portfolios of systematic strategies at CTA-specialist RPM Risk & Portfolio Management, Mr. Furelid’s focus areas include sytematic macro and CTAs. Jonathan can be reached at: jonathan@hedgenordic.com

Latest Articles

Diversification is Easy to Buy, Hard to Get: The Liquid Alternatives Test

By Luc Dumontier, CIO Global Asset Management, iM Global Partner: Rarely have global portfolios carried such concentrated exposure to a single bet. US equities...

Unlocking a Third Active Lever

By Steven Braun at Newfound Research and Return Stacked® Portfolio Solutions: Long-only active management traditionally has two levers for generating excess returns. The first...

Active and Alternative ETFs Gain Ground as Market Splits Between Cost and Value

The ETF market is entering a new phase in which growth is increasingly concentrated at opposite ends of the cost spectrum. While ultra-low-cost passive...

Beyond Passive: How Institutional Investors Are Reshaping Europe’s ETF Market

Flows into exchange-traded funds (ETFs) continue to show little sign of slowing, but the record asset growth tells only part of the story. Beneath...

Finding Leverage: From Ecology to Asset Management

By David Seekell: The biggest change since moving from academia to asset management is that I started getting advertisements for private jets in my...

Azpire Capital Brings Systematic Long/Short Strategy to Digital Assets

A trio of founders from Aarhus, Denmark, is launching a fund built around a systematic long/short strategy for digital asset markets. After almost two...

Allocator Interviews

In-Depth: Diversification

- Advertisement -

Voices

Request for Proposal

- Advertisement -